title: Changes in the activation level of NF-kappa B in lymphocytes of MS patients during glucocorticoid pulse therapy.
abstract: Nuclear factor-kappaB activity was analyzed in multiple sclerosis (MS) patients during the course of a methylprednisolone pulse therapy. Molecular effects were evaluated using lymphocytes derived from 20 MS patients before and after therapy and 24 healthy individuals. All patients responded to treatment clinically. The mean level of DNA-binding p65 in MS was proportionate to that of healthy controls, but was significantly decreased directly after therapy whereas the level of DNA-binding p50 was significantly elevated prior to therapy and remained unchanged. In summary, pulse therapy resulted in a decreased level of activated p65 NF-kappaB subunits leading to decreased levels of transcriptionally active pro-inflammatory NF-kappaB.
authors: Department of Internal Medicine, Rostock Clinic South, Südring 81, 18059 Rostock, Germany.
authors: Martin
authors: M
authors: Eggert
authors: Robert
authors: R
authors: Goertsches
authors: Ulrike
authors: U
authors: Seeck
authors: Silvia
authors: S
authors: Dilk
authors: Gunther
authors: G
authors: Neeck
authors: Uwe K
authors: UK
authors: Zettl
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D004268:DNA-Binding Proteins / Q000187:drug effects / Q000378:metabolism; D015536:Down-Regulation / Q000187:drug effects / Q000235:genetics; D004334:Drug Administration Schedule; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007249:Inflammation / Q000235:genetics / Q000276:immunology / Q000503:physiopathology; D008214:Lymphocytes / Q000187:drug effects* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood* / Q000188:drug therapy* / Q000235:genetics; D016328:NF-kappa B / Q000187:drug effects* / Q000378:metabolism; D051996:Transcription Factor RelA / Q000187:drug effects / Q000378:metabolism; D015533:Transcriptional Activation / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D004268:DNA-Binding Proteins; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016328:NF-kappa B; C498143:RELA protein, human; D051996:Transcription Factor RelA